Free Trial

Verona Pharma Q3 2024 Earnings Report

Verona Pharma logo
$58.09 -2.20 (-3.65%)
As of 04:00 PM Eastern

Verona Pharma EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.12
One Year Ago EPS
-$0.18

Verona Pharma Revenue Results

Actual Revenue
$5.62 million
Expected Revenue
$2.31 million
Beat/Miss
Beat by +$3.31 million
YoY Revenue Growth
N/A

Verona Pharma Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Remove Ads

Verona Pharma Earnings Headlines

[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.
See More Verona Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma and other key companies, straight to your email.

About Verona Pharma

Verona Pharma (NASDAQ:VRNA), a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

View Verona Pharma Profile

More Earnings Resources from MarketBeat